APPLIED DNA SCIENCES INC (APDN) Stock Price, Quote, News and Overview
NASDAQ:APDN - Nasdaq - US03815U5083 - Common Stock - Currency: USD
APDN Quote, Performance and Key Statistics
NASDAQ:APDN (7/2/2025, 2:18:26 PM)
4.5
-0.06 (-1.32%)
The current stock price of APDN is 4.5 USD. In the past month the price decreased by -21.78%. In the past year, price decreased by -98.62%.
APDN Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| TMO | THERMO FISHER SCIENTIFIC INC | 19.54 | 161.57B | ||
| DHR | DANAHER CORP | 27.22 | 145.12B | ||
| A | AGILENT TECHNOLOGIES INC | 22.37 | 34.44B | ||
| IQV | IQVIA HOLDINGS INC | 14.56 | 28.46B | ||
| MTD | METTLER-TOLEDO INTERNATIONAL | 29.85 | 25.10B | ||
| WAT | WATERS CORP | 29.67 | 21.03B | ||
| ILMN | ILLUMINA INC | 30.28 | 15.96B | ||
| WST | WEST PHARMACEUTICAL SERVICES | 33.34 | 15.91B | ||
| ICLR | ICON PLC | 11 | 11.99B | ||
| RVTY | REVVITY INC | 20.46 | 11.89B | ||
| QGEN | QIAGEN N.V. | 21.02 | 10.47B | ||
| TEM | TEMPUS AI INC | N/A | 10.29B |
Related stock screener links
About APDN
Company Profile
Applied DNA Sciences, Inc. is a biotechnology company, which engages in the development and commercialization of technologies to produce and detect deoxyribonucleic acid and ribonucleic acid. The company is headquartered in Stony Brook, New York and currently employs 46 full-time employees. The company went IPO on 2001-08-24. The firm is engaged in developing and commercializing technologies to produce and detect deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). The firm operates through three segments: Therapeutic DNA Production Services, MDx Testing Services, and DNA Tagging and Security Products and Services. Therapeutic DNA Production Services segment operations consist of the enzymatic manufacture of synthetic DNA for use in the production of nucleic acid-based therapeutics and, the development and sale of a proprietary RNAP for use in the production of messenger RNA (mRNA) therapeutics. MDx Testing Service segment operations consist of performing and developing clinical molecular diagnostic and genetic tests and clinical laboratory testing services. DNA Tagging and Security Products and Services segment operations consist of the manufacture and detection of DNA for industrial supply chains and security services.
Company Info
APPLIED DNA SCIENCES INC
50 Health Sciences Drive
Stony Brook NEW YORK 11790 US
CEO: James A. Hayward
Employees: 47
Phone: 16312408800
APPLIED DNA SCIENCES INC / APDN FAQ
What is the stock price of APPLIED DNA SCIENCES INC today?
The current stock price of APDN is 4.5 USD. The price decreased by -1.32% in the last trading session.
What is the ticker symbol for APPLIED DNA SCIENCES INC stock?
The exchange symbol of APPLIED DNA SCIENCES INC is APDN and it is listed on the Nasdaq exchange.
On which exchange is APDN stock listed?
APDN stock is listed on the Nasdaq exchange.
What is APPLIED DNA SCIENCES INC worth?
APPLIED DNA SCIENCES INC (APDN) has a market capitalization of 29.25M USD. This makes APDN a Nano Cap stock.
How many employees does APPLIED DNA SCIENCES INC have?
APPLIED DNA SCIENCES INC (APDN) currently has 47 employees.
What are the support and resistance levels for APPLIED DNA SCIENCES INC (APDN) stock?
APPLIED DNA SCIENCES INC (APDN) has a resistance level at 5.3. Check the full technical report for a detailed analysis of APDN support and resistance levels.
Is APPLIED DNA SCIENCES INC (APDN) expected to grow?
The Revenue of APPLIED DNA SCIENCES INC (APDN) is expected to grow by 50.26% in the next year. Check the estimates tab for more information on the APDN EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy APPLIED DNA SCIENCES INC (APDN) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of APDN, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of APDN, evaluating the profitability, health, valuation and growth aspects
- APPLIED DNA SCIENCES INC (APDN) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- APPLIED DNA SCIENCES INC (APDN) Sales and EPS estimates to see what analysts future expectations are.
- APPLIED DNA SCIENCES INC (APDN) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- APPLIED DNA SCIENCES INC (APDN) Insider and Institutional Ownership to learn about the owners and their transactions.
- APPLIED DNA SCIENCES INC (APDN) Stock Chart to make your own analysis
- APPLIED DNA SCIENCES INC (APDN) Latest news and press-releases to stay up to date.
Does APPLIED DNA SCIENCES INC (APDN) stock pay dividends?
APDN does not pay a dividend.
When does APPLIED DNA SCIENCES INC (APDN) report earnings?
APPLIED DNA SCIENCES INC (APDN) will report earnings on 2025-08-06.
What is the Price/Earnings (PE) ratio of APPLIED DNA SCIENCES INC (APDN)?
APPLIED DNA SCIENCES INC (APDN) does not have a PE ratio as the earnings reported over the last twelve months were negative (-537.75).
APDN Technical Analysis
APDN Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to APDN. APDN scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
APDN Financial Highlights
Over the last trailing twelve months APDN reported a non-GAAP Earnings per Share(EPS) of -537.75. The EPS increased by 95.81% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -354.31% | ||
| ROE | -441.56% | ||
| Debt/Equity | 0 |
APDN Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 43% to APDN. The Buy consensus is the average rating of analysts ratings from 6 analysts.
For the next year, analysts expect an EPS growth of 92.97% and a revenue growth 50.26% for APDN